



CURRICULUM VITAE

Dr. Nimer Alkhatib, PharmD, MS, PhD


*Pharmacy/Assistant Professor of Pharmacoeconomics,
Policy, and Health Outcomes*

Al-Zaytoonah University of Jordan, Amman, Jordan

Phone: 00962-6-4291511

Fax: 00962-6-4291432

E-mail: n.alkhatib@zuj.edu.jo



1. Personal Data

Date of Birth: 2 January 1987 (Manhattan, KS, USA)
Nationality: USA and Jordan

2. Education

- Ph.D. (Pharmaceutical economics, policy, and health outcomes) 2019, University of Arizona, Tucson, Arizona, USA
- Certificate (Business Entrepreneurship), 2019 Arizona State University (ASU), Phoenix, Arizona
- M.Sc. (Pharmaceutical economics, policy, and health outcomes) 2017, University of Arizona, Tucson, Arizona, USA
- B.Sc. (PharmD) 2011, Jordan University of Science and Technology, Irbid, Jordan

3. Ph.D. Dissertation

Innovative methods for outcome-based pricing treatments from the US payer perspective (the six delta platform)-University of Arizona, Tucson, USA.

4. Employment

Academic Positions



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

- Assistant Professor of Pharmacoeconomics, Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
February 23, 2020 – now
- Adjunct Assistant Professor, Pharmacy practice and science, University of Arizona, Tucson, USA
February 20, 2020 – Now
- Designated Campus Colleague/ Associate, Center for Health Outcomes and PharmacoEconomic Research (HOPE Center), University of Arizona, USA
March 7, 2020 – Now
- Pre-doctoral fellow, Center for Health Outcomes and PharmacoEconomic Research (HOPE Center), University of Arizona, USA
August 15, 2015, December 30, 2019

Research Positions

- Editorial Board Consultant/ Journal of Clinical Therapeutics (IF= 3), Philadelphia, USA
2017, Now
- Hematology/Oncology Research Group Leader/ Center for Health Outcomes and PharmacoEconomic Research (HOPE), Arizona, USA
2017, 2020

5. Research Interests

- Value-based pricing, Oncology, Biosimilars, Cost-effectiveness, Modelling, Outcome Research.

6. Honors and Awards

- Academic excellence, 2016, University of Arizona, USA
- Academic excellence, 2017, University of Arizona, USA
- Academic excellence, 2018, University of Arizona, USA
- Academic excellence, 2019, University of Arizona, USA

7. Fellowships and Scholarships

- Full scholarship-PhD in Pharmacoeconomics, policy, and health outcome- Sponsored by the University of Arizona, USA 2017-2019
- Partial Scholarship- Certificate of Business Entrepreneurship sponsored by Arizona State University (ASU)
- Full scholarship-Summer School-Genomics and Science of Symptom Management by the University of Basel, Switzerland 2016-2016
- Full scholarship-MS in Pharmacoeconomics, policy, and health outcome- Sponsored by the University of Arizona, USA 2015-2019



9. Teaching Experience

• *Graduate Courses*

- Health Technology Assessment. College of Pharmacy, University of Arizona, Tucson, USA
- Applied Health Technology Assessment, College of Pharmacy, University of Arizona, Tucson, USA

• *Undergraduate Courses*

- Pharmacoeconomics, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
- Pharmaceutical marketing, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
- Pharmacy Practice (applied), College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

10. Supervision of Graduate Research

- Evelyn Kim: For senior project-PharmD. University of Arizona 2016-2017
- Yazan Barqawi: For Master's degree in Pharmaceutical Economics. University of New Mexico 2017-2018
- Neda Alrawashdh: For Master's degree in Clinical Translational Sciences. University of Arizona 2018-2020
- Briana Choi: For senior project-PharmD. University of Arizona 2018-2019
- Elizabeth Pae: For senior project-PharmD. University of Arizona 2018-2019
- Kelly Yiu: For senior project-PharmD. University of Arizona 2018-2019

11. Grants

- Principal investigator. Economic evaluation of f Olanzapine, neurokinin-1 receptor antagonist, and thalidomide in combination with palonosetron and dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Umm Al-Qura University, Makkah, Saudi Arabia. Budget: Confidential
- Analyst. Evaluation of smoking cessation clinics and behavior of clients. Department of Family Medicine/ College of Medicine/ University of Arizona. Under Prof. Ivo Abraham. Budget: Confidential
- Analysis group leader "Economic evaluation of smoking cessation vs. persistence for a panel of ~200,000 Arizonans who quit cigarette smoking

between 1/1/2011 and 12/31/2015.” Arizona Department of Health Services (2017-2018). Direct costs: \$213,450.

12. Professional and Scientific Meetings

Scientific Meetings Organized

- IPSF meeting 2011. Qatar University. Doha. Qatar.
- Clinical Pharmacy Day 2010. Jordan University of Science and Technology. Irbid. Jordan

Participation in Scientific meetings

Abstracts presented and published

1. **Alkhatib N**, Choi B, Pae E, Babiker H, Garland L, Henglefeld A, McBride A, Abraham I. Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS). American Society of Clinical Oncology (ASCO) 2019 USA.
2. Choi B, **Alkhatib N**, Pae E, Babiker H, Garland L, Henglefeld A, McBride A, Abraham I. Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) 2019 USA.
3. Alrawashdh N, **Alkhatib N**, McBride A, Persky D, Abraham I. Economic Evaluation for the US of Ibrutinib versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. American Society of Hematology (ASH) 2018 USA
4. **Alsaid N**, McBride A, Abraham I. Economic Evaluation for the US of Ibrutinib versus Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Clinical Oncology (ASCO) 2018 USA
5. Oh M, Almutairi A, **Alsaid N**, Babiker H, McBride A, Abraham I. Progression-Free(PFS) and Overall Survival (OS) in Treatment of BRAF Mutation-Positive Metastatic Melanoma: Bayesian Network Meta-Analysis. American Society of Clinical Oncology (ASCO)2018 USA
6. **Alsaid N**, McBride A, Oh M, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
7. **Alsaid N**, McBride A, Kim H, Oh M, Andritsos L, Anwar F, Persky D, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Ibrutinib versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
8. **Alsaid N**, Sweitzer N, Ramos N, Abraham I. Systematic Review for Causes of Hospitalization in Cost-Effectiveness Studies. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Europe



9. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Economic Evaluation of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). World Congress of Pharmacy and Pharmaceutical Sciences (FIP) 2017 South Korea
10. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Cost-Effectiveness of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). American Society of Clinical Oncology (ASCO) 2017 USA
11. **Alsaid N**, McBride A, Abraham I. Cost-effectiveness of Daratumumab 10mg+Dacarbazine versus Dacarbazine Alone in Metastatic/Advanced Melanoma. Western Pharmacoeconomics Conference 2017 USA
12. **Alsaid N**, Almutairi A, Fazel M, Lee J, Slack M. Information Required in Research Reports for Inclusion in Meta- analysis: Cohort Studies for Evaluating the Impact of Pharmacist Care on Diabetes Outcomes. American Society of Health-System Pharmacists (ASHP) midyear scientific sessions 2016 USA

13. Presentations and Lectures Invited

- **Alkhatib N**. Applied Health Technology. Center for Health Outcomes and PharmacoEconomic Research, Tucson, USA. Spring Semester 2020
- **Alkhatib N**. Feasibility of health care services in Jordan. Jordanian Ministry of Health, Amman, Jordan. Spring 2020
- **Alkhatib N**. Value-Based Pricing of treatments in developed countries. Jordanian Food and Drug Administration. Amman, Jordan. August 2019
- **Alkhatib N**. The Evolving Role of the Oncology Pharmacy: Multidisciplinary Perspectives Pre-Conference (Panel Discussion). Association of Community Cancer Centers, ACCC 35th National Oncology Conference, Phoenix, USA, October 2018
- **Alkhatib N**. Role of Biosimilars in Value-Based Care (Panel Discussion). Association of Community Cancer Centers, ACCC 35th National Oncology Conference, Phoenix, USA, October 2018
- **Alkhatib N**. Introduction to Health Economics in USA, and Countries of Gulf Cooperation Council (GCC). Center for Health Outcomes and PharmacoEconomic Research (HOPE). Summer post-doc training, University of Arizona, Tucson, USA, Summer 2018
- **Alkhatib N**. Future of International Pharmaceutical Students' Federation (IPSF) in Eastern Mediterranean Region. Regional IPSF Symposium, University of Qatar, Doha, Qatar, June 2011

14. Invited Interviews

- **Alkhatib N**. Integrating Biosimilars Within a Community, Academic, or Health-System Setting. 2019: <https://www.accc->



[cancer.org/home/learn/immunotherapy/resource-detail/integrating-biosimilars-within-a-community-academic-or-health-system-setting](https://www.cancer.org/home/learn/immunotherapy/resource-detail/integrating-biosimilars-within-a-community-academic-or-health-system-setting)

- **Alkhatib N**, McBride A, Earl M, Patel K. Expert Panel Discusses the Financial and Economic Impact of Biosimilars Targeted Oncology 2018.
<https://www.targetedonc.com/conference/accc-noc-2018/expert-panel-discusses-the-financial-and-economic-impact-of-biosimilars>
- **Alsaid N**. Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia. AJMC Managed Markets Network 2018.
<https://www.ajmc.com/conferences/ash-2017/ibrutinib-more-effective-than-stemcell-transplant-in-patients-with-form-of-chronic-leukemia>

15. Organizational Services

- Research Group Leader for Arizona Health Department Funded Project, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2017-present).
- Hematology and Oncology Research Group Leader, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2016-present).
- Post-Doc Trainer, Center for Health Outcome and PharmacoEconomic Research (THE HOPE CENTER). (2016- present).
- Social Chair, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), University of Arizona Chapter (2016-2017).
- Regional Project Officer, International Pharmaceutical Students' Federation (IPSF), Eastern Mediterranean Region (2010-2011)
- Member, Jordanian Pharmaceutical Association. Jordan (2011-present).

16. Publications

Peer Reviewed Articles

Submitted

1. Oh M, Patanwala A, **Alkhatib N**, Almutairi A, Abraham I, Erstad B. Cost analysis of adjunctive hydrocortisone therapy for septic shock: US payer perspective. Critical Care Medicine.
2. Abraham I, Sun D, Denhaerynck K, Hamarneh D, Van Camp Y, Villa L, **Alkhatib N**, Brié H, Vancayzeele S, MacDonald K. Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment: pooled analysis of six prospective real-world studies including 11,999 patients. Vascular Health and Risk Management.
3. Hamarneh D, **Alkhatib N**, Denhaerynck K, Vancayzeele S, Brié H, MacDonald K, Abraham I. Hierarchical modeling of gender-specific determinants of outcomes of antihypertensive treatment: pooled analysis of seven prospective real-world studies including 17,044 patients. Journal of Human Hypertension.

Published

4. Andritsos LA, Huang Y, Abraham I, Huff K, Scrape SR, Fan T, **Alkhatib N**, Hofmeister CC, Drea E, McBride A. Clinical and cost outcomes of pre-emptive



- plerixafor administration in patients with multiple myeloma undergoing stem-cell mobilization. *Leukemia Research* 2019;85:106215
5. Alfayez O, AlYami M, Alshibani M, Fallataha S, AlKhushaym N, Alsheikh R, **Alkhatib N**. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. *Journal: Primary Care Diabetes* 2019.
 6. Almutairi AR, **Alkhatib N**, Martin J, Babiker H, Garland L, McBride A, Abraham I. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: a Bayesian network meta-analysis. *Critical Reviews in Oncology and Hematology* 2019;142:16-25.
 7. Almutairi AR, **Alkhatib N**, Abraham I. The importance of outcome and precise evaluation in economic evaluation of cancer drugs – Reply. *JAMA Dermatology* 2019;155:863.
 8. Almutairi AR, **Alkhatib N**, Oh M, Curiel-Lewandrowski C, Babiker HM, Cranmer L, McBride A, Abraham I. Economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy versus ipilimumab in patients with advanced unresectable melanoma. *JAMA Dermatology* 2019;155:22-28
 9. Kelley EF, Snyder EM, **Alkhatib N**, Snyder SC, Sprissler R, Olson TP, Abraham I. Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. *Journal of Medical Economics* 2018;21:1246-1253.
 10. Gharaibeh M, McBride A, Alberts DS, Erstad B, Slack M, **Alsaid N** Bootman JL, Abraham I. Economic evaluation for the UK of systemic chemotherapies in first-line treatment of metastatic pancreatic cancer. *PharmacoEconomics* 2018;36:1333-1343.
 11. **Alkhatib N**, Ramos K, Gharaibeh M, Slack M, Erstad B, Karnes J, Klimecki W, Sweitzer NK, Abraham I. Economic evaluation of genetic testing for Arg389 in the management of stage III/IV heart failure. *Expert Review of Precision Medicine and Drug Development* 2018;3:319-329.
 12. Gharaibeh M, McBride A, Alberts DS, Slack M, Erstad B, **Alsaid N**, Bootman JL, Abraham I. Economic evaluation for USA of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer. *PharmacoEconomics* 2018;36:1273-1284.
 13. Zhou L, Almutairi L, **Alsaid N**, Warholak T, Cooley J. Establishing the Validity and Reliability Evidence of Preceptor Assessment of Student Tool Designed to Assess Rotation Performance of Doctor of Pharmacy Students: A Rasch Analysis. *American Journal of Pharmaceutical Education (AJPE)* 2016

Abstracts Accepted

1. **Alkhatib N**, Choi B, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS). *American Society of Clinical Oncology (ASCO)* 2019 USA.



QFG11/0110 - 3.1E

Curriculum Vitae Form - Procedures of Appointment and Promotion Committee

2. Choi B, **Alkhatib N**, Pae E, Babiker H, Garland L, Henglefeldt A, McBride A, Abraham I. Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). American Society of Clinical Oncology (ASCO) 2019 USA.
3. Alrawashdh N, **Alkhatib N**, McBride A, Persky D, Abraham I. Economic Evaluation for the US of Ibrutinib versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. American Society of Hematology (ASH) 2018 USA
4. **Alsaid N**, McBride A, Abraham I. Economic Evaluation for the US of Ibrutinib versus Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Clinical Oncology (ASCO) 2018 USA
5. Oh M, Almutairi A, **Alsaid N**, Babiker H, McBride A, Abraham I. Progression-Free(PFS) and Overall Survival (OS) in Treatment of BRAF Mutation-Positive Metastatic Melanoma: Bayesian Network Meta-Analysis. American Society of Clinical Oncology (ASCO)2018 USA
6. **Alsaid N**, McBride A, Oh M, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Venetoclax versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
7. **Alsaid N**, McBride A, Kim H, Oh M, Andritsos L, Anwar F, Persky D, Kumar A, Yun S, Abraham I. Economic Evaluation for the US of Ibrutinib versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion. American Society of Hematology (ASH) 2017 USA
8. **Alsaid N**, Sweitzer N, Ramos N, Abraham I. Systematic Review for Causes of Hospitalization in Cost-Effectiveness Studies. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2017 Europe
9. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Economic Evaluation of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). World Congress of Pharmacy and Pharmaceutical Sciences (FIP) 2017 South Korea
10. **Alsaid N**, McBride A, Agarwal A, Mutairi A, Anwer F, Abraham I. Cost-Effectiveness of Carfilzomib (CAR), Ixazomib (IXA), Elotuzumab (ELO), or Daratumumab (DAR) with Lenalidomide & Dexamethasone (LEN+DEX) vs LEN+DEX in Relapsed/Refractory Multiple Myeloma (R/R MM). American Society of Clinical Oncology (ASCO) 2017 USA
11. **Alsaid N**, McBride A, Abraham I. Cost-effectiveness of Daratumumab 10mg+Dacarbazine versus Dacarbazine Alone in Metastatic/Advanced Melanoma. Western Pharmacoeconomics Conference 2017 USA
12. **Alsaid N**, Almutairi A, Fazel M, Lee J, Slack M. Information Required in Research Reports for Inclusion in Meta- analysis: Cohort Studies for Evaluating the Impact of Pharmacist Care on Diabetes Outcomes. American Society of Health-System Pharmacists (ASHP) midyear scientific sessions 2016 USA



QFG11/0110 - 3.1E	Curriculum Vitae Form - Procedures of Appointment and Promotion Committee
-------------------	---